AMGN - Arvinas IPO: 40% Is Cash But Research Is At An Early Stage
With Yale University, Pfizer Inc. (PFE), Roche Ltd. (RHHBY) and Merck (MRK) collaborating with Arvinas Holding (ARVN) and shares at 2.5 its cash per share, the company seems a name that should retain the attention of investors. Having said that, Arvinas, which conducts research treatments against breast and prostate cancer, is still at an early stage, and relevant data will not be released until 2019. Investors may not appreciate this fact and may prefer to wait a year or two until stock catalysts are closer.
Source: Prospectus